Comment:đź©ş This study of 390 paired primary and metastatic breast cancers provides some of the most compelling institutional data to date, confirming the biological profile of a breast cancer can and often does change dramatically upon metastasis. The sheer magnitude of the discordance rates—especially the 40.3% change for Progesterone Receptor (PR) and the 18.3% change […]
đź“ť Comment: This trial provides a critical, high-level confirmation: modern systemic therapy has fundamentally changed the risk/benefit profile of post-mastectomy chest-wall irradiation (CWI) for intermediate-risk breast cancer. The key takeaway is that for the overall population, a minimal absolute reduction in local recurrence (less than 2 percentage points) did not translate into an Overall Survival […]
Comment: This 2017 article’s real contribution here isn’t the narrative review—which, as is too selective to be high-quality—but the new VICTOR-2 subgroup data. While a 35.7% Clinical Benefit Rate in an elderly (median age 69) metastatic TNBC population is certainly interesting, it’s from a tiny, single-arm cohort of 28 patients. This paper highlights metronomic chemotherapy […]
Comment: This paper tries to identify the true clinical niche for Metronomic Chemotherapy: adjuvant maintenance therapy for patients with residual disease. This is the high-risk subgroup where the gold standard, maximum tolerated dose (MTD) chemotherapy, has clearly failed to eradicate the disease. The success of the CREATE-X trial in this specific, defined population—with its remarkable […]
Comment: This study presents a very practical and appealing option for managing advanced HER2-negative breast cancer in the palliative setting. The key takeaway is the dual advantage of this all-oral metronomic regimen: it demonstrates clinically relevant activity while maintaining an exceptionally low toxicity profile. However, the regimen’s main strength is its safety and convenience. Being […]
